Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label GLPG1837 dose-escalation study in adults with cystic fibrosis and S1251N mutation
NL-OMON43806Phase 2Active, not recruiting
- Sponsor
- Galapagos NV
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GLPG1837 in cystic fibrosis (CF), sponsored by Galapagos NV. Primary endpoint: Safety and tolerability. Started Apr 2016; status: active, not recruiting.
02
Drugs
GLPG1837
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON43806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43806.